Rybrevant Partial Change Approval
Amivantamab (genetical recombination)
Approval Information
Brand NameRybrevant
Partial Change Approval
Generic NameAmivantamab (genetical recombination)
ApprovedMarch 2025
TypeInitial Approval
Review Reports
Want structured data, translation summaries & alerts?
PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.
Join the WaitlistSource: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.